Laurus Labs Ltd Q3FY24; 89% fall in Profits

Founded in 2005, Laurus Labs is a research-driven pharmaceutical and biotechnology company having a global leadership position in select Active Pharmaceutical Ingredients (APIs) including anti-retroviral, oncology drugs (incl High Potent APIs), Cardiovascular, and Gastro therapeutics. They also offer integrated CMO and CDMO services to Global Innovators from Clinical phase drug development to commercial manufacturing. Laurus employs 6500+ people, including around 1050+ scientists at more than 11 facilities approved by global agencies USFDA, WHO-Geneva, Japan PDMA, UK-MHRA, EMA, TGA etc.

Financial Results:

Laurus Labs Ltd reported Revenues for Q3FY24 of ₹1,195.00 Crores down from ₹1,545.00 Crore year on year, a fall of 22.65%.

Total Expenses for Q3FY24 of ₹1,163.00 Crores down from ₹1,268.00 Crores year on year, a fall of 8.28%.

Consolidated Net Profit of ₹23.00 Crores down 88.67% from ₹203.00 Crores in the same quarter of the previous year.

The Earnings per Share is ₹0.43, down 88.59% from ₹3.77 in the same quarter of the previous year.

*It is important to note that the way the results have been accounted for are slightly different than the ones the companies may choose to publish.

*The presented data is automatically generated. It may occasionally generate incorrect information.